Inhalation Sciences - DCF-analys visar nuvärde 200% högre än dag
I detta blogginlägg tittar vi närmare på Inhalation Sciences tillväxt, uttalanden från VDn och kommande triggers. Denna analys visar ett nuvärde på 31 kr/aktie (alltså det värde vi borde ha idag), och inkluderar då inte dotterbolaget Ziccum:
https://www.redeye.se/arena/posts/isab
https://www.redeye.se/arena/posts/isab
Redigert 19.01.2021 kl 05:49
Du må logge inn for å svare
Twitter update from ISAB:
"Really looking forward to meeting our customer Fraunhofer ITEM again at their "Models of Lung Disease" Seminar, Hanover Jan' 18-19! It's their 7th Translational Airway Research Seminar. Can't wait to meet & mingle with other toxicology pioneers!"
https://twitter.com/InhalationMark/status/953561307638370304
"Really looking forward to meeting our customer Fraunhofer ITEM again at their "Models of Lung Disease" Seminar, Hanover Jan' 18-19! It's their 7th Translational Airway Research Seminar. Can't wait to meet & mingle with other toxicology pioneers!"
https://twitter.com/InhalationMark/status/953561307638370304